CVS Reinstates Zepbound Coverage and Adds Lilly’s Foundayo Obesity Pill

CVS Caremark will restore Eli Lilly’s obesity drug Zepbound to its commercial formularies on October 1 and add Lilly’s obesity pill Foundayo as a co‑preferred option, aiming to provide equal access and copays with Novo Nordisk’s Wegovy (as low as $25 a month for eligible commercially insured patients). All three of the nation’s largest pharmacy benefit managers now cover Lilly’s obesity portfolio, a move that could boost Foundayo sales in the second half of the year as employers and health plans seek more affordable GLP‑1 weight‑loss options.